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mild MR at baseline were in NYHA class III or IV.
Conclusion: Moderate or severe MR in patients undergoing TAVR is associated with
a higher short-term, but not long-term, mortality. MR improves in approximately half
of the patients with moderate or severe MR post TAVR.
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Background: The randomized PARTNER trial excluded patients with conditions
frequently encountered in clinical practice.
Methods: 242 consecutive high-risk patients (STS >10) undergoing trancatheter aortic
valve implantation (TAVI) were assessed. Patients were divided into a “PARTNER-
exclusions” (PE) group (ejection fraction <20%, severe mitral regurgitation, creatinine
>3.0 mg/dl and/or hemodialysis, significant coronary disease, recent coronary stenting,
cerebrovascular accident within 6-months, annulus diameter <16mm/>24mm, bicuspid
valve, aortic regurgitation >3+, prior valve surgery) and “no PARTNER exclusion”
(NPE) group. The last 4 criteria were also sub-analyzed as “technical exclusions”.
Results: 12-month KM-survival estimates for the PE group were 68.1% vs. 78.2% for
the NPE group (p=0.14). At 3-years this was 40.1% vs. 61.9%, p=0.04. The unadjusted
HR for 3-year mortality for the PE group was 1.61 (95% CL 1.01-2.56), but when
adjusted for baseline differences using a proportional hazard model this was no longer
significant–HR 1.36 (95%CL 0.79-2.35). There were no significant differences in
adjusted survival between the technical groupings either within 30-days (p=0.60) or
1-year (p=0.07). Technical exclusions were not associated with procedural failures and
procedural success rates were excellent (>98%). Ejection fraction <20% trended
(p=0.053) towards lower unadjusted 12-month survival. Patients with severe mitral
regurgitation had similar 12-month survival compared to those without severe
regurgitation.
Conclusion: Patients undergoing TAVI who meet exclusion criteria for the PARTNER
trial represent a high-risk cohort with higher unadjusted long-term mortality, but similar
long-term outcomes when adjusted for baseline risk. Patients with technical exclusion
criteria can still have highly successful procedures. This has important implications
for selection of patients with future “off –label” indications.
TCT-766
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Background: To compare the predictors of high grade atrio-ventricular block (AVB)
after transcatheter aortic valve replacement (TAVR) with the Edwards-Sapien™ THV
(Edwards Lifesciences, Irvine, California) (ESV) and CoreValve ReValving System®
(CoreValve Medtronic Inc, Minneapolis, Minnesota, USA) (CVR)
Methods: We included all consecutive patients undergoing successful TAVR in our
center from November 2007 to March 2011; we excluded 25 patients who had already
a permanent pacemaker and 24 patients whom electrocardiography analysis were not
available.
Results: The study cohort comprised 228 patients: 85 CVR and 143 ESV. Fifty-percent
of the patients were male (63.5% in CVR vs. 46.2% in ESV; p=0.01) and the mean
age was 79±7 years. The patients who underwent TAVR with CVR had a higher
prevalence of poor LVEF (20.0% vs. 10.5%; p=0.04). Baseline electrocardiography
showed a higher prevalence of left bundle brunch block (LBBB) in the CRV then ESV
group (21.2% vs. 8.4%; p=0.006), similar prevalence of right bundle brunch block
(RBBB) (16.5% vs. 13.3%; p=0.50) and wider QRS complex in the CRV then ESV
group (112.6±27.1 ms vs. 105.7±23.4 ms; p=0.04). The incidence of high degree AVB
was higher after CVR (n=15) then ESV (n=10) implantation (17.6% vs. 7.0%; p=0.01).
The multivariable predictors of AVB after TAVR were CVR vs. ESV implantation (OR
2.43, 95%CI 1.00-5.91; p=0.05) and wider baseline QRS (OR 1.02, 95%CI 1.01-1.04;
p<0.001). The univariate predictors of AVB after CVR implantation were the RBBB
(OR 7.87, 95%CI 2.18-28.32; p=0.002) and the wider QRS complex (OR 1.04, 95%CI
1.01-1.06; p<0.001), meanwhile poor LVEF (OR 7.39, 95%CI 1.81-30.21; p=0.005)
and the depth of prosthesis implantation (OR 1.45, 95%CI 1.0-2.06; p=0.03) were the
univariate predictors of AVB after ESV implantation.
Conclusion: The main predictors of AVB after TAVI seem to be the CVR vs. ESV
implantation and a wider QRS complex. RBBB and the wider QRS complex seem to
be predictors in case of CVR implantation, whereas poor LVEF and the depth of
prosthesis implantation seem to be predictors of AVB in the case of ESV implantation.
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Background: Gender differences in patients undergoing surgical aortic valve
replacement are well documented. Whether gender differences exist in patients
undergoing TAVI is unknown.
Methods: From June 2007 to June 2010, we enrolled 333 consecutive patients who
underwent Medtronic CoreValve implantation. Baseline characteristics and clinical
outcomes were prospectively entered into a dedicated database and differences between
genders were investigated. The primary end-point consisted of a composite outcome
of 1-year mortality.Differences in survival outcomes between genders were estimated
by Kaplan-Meier survival curves.
Results: 152 (46%) were male and 181 (54%) were female. Males had a larger left
ventricular end-diastolic dimensions (51.5 ± 7.7 vs. 45.07 ± 7 mm, p<0.001) and aortic
annulus size (25 ± 1.04 vs. 22.6 ± 1.5 mm, p<0.001) than females. Females were
characterized by higher transaortic mean gradient(49.7 ± 17.7 vs. 45 ± 16 mmHg, p=
0.013). Males were more likely to have coronary artery disease (61.2 vs. 44.7%, p=
0.003) and previous history of coronary artery bypass surgery (28 vs. 6.6%, p<0.001),
more peripheral arterial disease (28 vs. 10.5%, p<0.001), higher baseline creatinine
levels (1.36 ± 0.5 vs. 1.07 ± 0.47 mg/dl, p=<0.001), lower ejections fraction <35%
(23.4 vs. 8.4%, p<0.001), and higher logistic EuroSCORES (21.4 ± 14.4 vs. 17.4 ±
10.7%, p= 0.007). A 26-mm CoreValve was implanted in 62% of females and a 29-
mm CoreValve in 79% in males. Kaplan-Meier survival analyses did not demonstrate
any differences between genders with regards to 30-day or 1-year mortality. Males
were more likely to require post-implant dilatation (28.6 vs. 16.9%, p= 0.011) for
significant paravalvular aortic regurgitation whereas females had a higher occurrence
of post-procedural pericardial effusion > 1cm (4.4 vs. 0%, p= 0.009).
Conclusion: In the current study, males undergoing TAVI had more comorbidities and
higher logistic EuroSCORES than females. There were no significant differences in
30-day or 1-year mortality between genders.
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Background: Prosthesis embolization during transcatheter aortic valve implantation
(TAVI) is a rare but important complication, and data on prosthesis performance placed
far from its anatomic position are sparse. We sought to investigate the causes of self-
expanding CoreValve embolization during TAVI and mid-term follow-up of patients
experiencing this acute complication.
Methods: Among 176 consecutive patients undergoing TAVI with CoreValve
prosthesis, 7 (3.9%) experienced acute valve embolization. Accurate analysis of
mechanism of embolization, clinical outcomes and performance of embolized
prosthesis were investigated.
Results: The reasons of valve embolization were classified into three groups: 1)
accidental embolization immediately after valve implantation (N=1; 14.3%) 2)
Embolization during snaring maneuver to reposition a low deployment of the CRS
prosthesis (lower edge >10 mm) below the aortic annulus accompanied with
hemodynamically significant regurgitation (N=4; 57.1%); 3) intentional embolization
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